Handling Extraordinary Events in Comparability

Extraordinary and non-recurring items are the single most common source of a single comparable sitting miles outside an otherwise tight range. How you treat them — exclude the company, exclude the year, or adjust the data — should be a deliberate, documented decision, not an afterthought.

The Indian TP framework does not define “extraordinary” as a screening category. Comparability analysis requires the tested party and comparables to be compared on the same basis, so the question is always: does the item distort the underlying profitability that the PLI is meant to measure?

Categories of non-recurring items

Type of item	Examples	Typical treatment
One-off gains	Asset sales, insurance proceeds, subsidy receipts	Exclude from operating income if clearly capital / non-operating
One-off losses	Litigation settlements, write-downs, penalties	Exclude from operating costs, or document the year
Structural events	Merger, demerger, business transfer	Usually exclude the affected year entirely
Exceptional years	Demand shocks, COVID-style shutdowns, supply disruption	Consider excluding the year from multi-year averages
Foreign exchange spikes	Unhedged currency exposure in a volatile year	Treat consistently with the PLI convention adopted

The exclusion principle

Rule 10D’s documentation requirements — and the way TPOs actually read an Accept-Reject matrix — reward a single consistent principle: an item is excluded only when it distorts the arm’s-length return from the controlled activity. Apply it the same way to every company, or the matrix becomes an argument that the range was manufactured.

Three defensible treatments exist, in order of preference:

1. Adjust the data. Where a one-off item is identifiable and separable from the comparable’s operating results, restate the margin excluding it. This keeps the comparable in the pool and is the least destructive option.
2. Exclude the year. Where the distortion is pervasive (a full-year demand shock, a merger), drop that financial year from the comparable’s multi-year average rather than the company.
3. Exclude the company. Where the item cannot be quantified and the company is unrepresentative, reject it with a documented reason — exactly as you would for any qualitative screen.

Practical screening steps

• Scan the profit-and-loss statement for income and expense items labelled “exceptional”, “extraordinary”, “non-recurring”, or unusual in size relative to operating revenue.
• Ask whether the item passes through the PLI. An operating-margin PLI captures it; a cost-plus PLI may not. The treatment must match the PLI you actually use.
• Be consistent across years. If you exclude a comparable’s COVID-year, do the same for the tested party’s own exceptional year, or disclose why not.
• Document each decision at screening time. Reasons written while the exception is fresh are credible; reasons reconstructed during assessment are not.

What survives TPO review

A defensible treatment is a documented treatment. The working paper for every impacted comparable should record: the item identified, why it is non-operating or non-recurring, the exact treatment applied, and the margin before and after. This mirrors the exclusion-rationale discipline that Rule 10D demands for the Accept-Reject matrix as a whole.

When in doubt, prefer the smallest intervention that restores comparability. Excluding an entire company for a single separable one-off gain is usually a sign the quantitative screen did the job for the wrong reason.

For the screening framework these decisions slot into, see the methods overview; for the documentation burden that follows every exclusion, the Rule 10D checklist.

Screen exceptional years consistently

TP Analytics flags exceptional and non-recurring items across the pool and records your treatment choice for every comparable, so the matrix stays consistent.

Book a Demo